{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:12:07Z","timestamp":1793747527997,"version":"4.6.1"},"reference-count":175,"publisher":"Bentham Science Publishers Ltd.","issue":"12","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDT"],"published-print":{"date-parts":[[2020,9,18]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p> Corneal neovascularization (CN) is a clue feature of different ocular pathological\nconditions and can lead to corneal edema and opacification with subsequent vision loss. Vascular\nendothelial growth factor (VEGF), which plays a key role in new vessels formation, proliferation\nand migration, was found to be up-regulated in these conditions. Nowadays, it is possible to downregulate\nthe angiogenic process by using anti-VEGF agents administered by different routes.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>To evaluate the efficacy, safety and possible future directions of anti-VEGF agents used for\nthe treatment of CNV owing to different aetiologies.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p> A computerized search of articles dealing with the topic of anti-VEGF therapy in CN was\nconducted in PubMed, Scopus and Medline electronic databases. The following key phrases were\nused: anti-VEGF agents, corneal neovascularization, bevacizumab, ranibizumab, vascular endothelial\ngrowth factor, angiogenesis.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The use of anti-VEGF therapy in the treatment of CN reduced pathological vessel density\nwithout causing significant side effects. Various administration routes such as topical, subconjunctival\nand intrastromal ones are available, and the choice depends on patient and disease characteristics.\nMuch more effectiveness is achieved in case of early administration before mature and wellestablished\nvessels take place. A combined approach between various drugs including anti-VEGF\nagents should be adopted in those cases at higher risk of neovascularization recurrence such as chronic\nlong-standing diseases where ischemic and inflammatory stimuli are not definitively reversed.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>The efficacy and safety of anti-VEGF agents support their adoption into the daily clinical\npractice for the management of CN.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389450121666200319111710","type":"journal-article","created":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T12:30:26Z","timestamp":1584621026000},"page":"1159-1180","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Anti-VEGF Treatment in Corneal Diseases"],"prefix":"10.2174","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2617-0289","authenticated-orcid":true,"given":"Giuseppe","family":"Giannaccare","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, University Magna Graecia of Catanzaro, Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6419-6941","authenticated-orcid":true,"given":"Marco","family":"Pellegrini","sequence":"additional","affiliation":[{"name":"Ophthalmology Unit, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Bovone","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Ospedale Privato \u201cVilla Igea\u201d, Forli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Spena","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Ospedale Privato \u201cVilla Igea\u201d, Forli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlotta","family":"Senni","sequence":"additional","affiliation":[{"name":"Ophthalmology Unit, University of Bologna, Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Scorcia","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University Magna Graecia of Catanzaro, Catanzaro, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Busin","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Ospedale Privato \u201cVilla Igea\u201d, Forli, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2006.09.002","volume":"26","author":"Zhang S.X.","year":"2007","unstructured":"Zhang S.X.; Ma J.X.; Ocular neovascularization: Implication of endogenous angiogenic inhibitors and potential therapy. Prog Retin Eye Res 2007,26(1),1-37","journal-title":"Prog Retin Eye Res"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.preteyeres.2006.09.001","volume":"25","author":"Ma D.H.","year":"2006","unstructured":"Ma D.H.; Chen J.K.; Zhang F.; Lin K.Y.; Yao J.Y.; Yu J.S.; Regulation of corneal angiogenesis in limbal stem cell deficiency. Prog Retin Eye Res 2006,25(6),563-590","journal-title":"Prog Retin Eye Res"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s00417-019-04301-6","volume":"257","author":"Giannaccare G.","year":"2019","unstructured":"Giannaccare G.; Pellegrini M.; Bernabei F.; Scorcia V.; Campos E.; Ocular surface system alterations in ocular graft-versus-host disease: all the pieces of the complex puzzle. Graefes Arch Clin Exp Ophthalmol 2019,257(7),1341-1351","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1001\/jamaophthalmol.2017.3204","volume":"135","author":"Busin M.","year":"2017","unstructured":"Busin M.; Giannaccare G.; Sapigni L.; Conjunctival and Limbal Transplantation From the Same Living-Related Bone Marrow Donor to Patients With Severe Ocular Graft-vs-Host Disease. JAMA Ophthalmol 2017,135(10),1123-1125","journal-title":"JAMA Ophthalmol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1097\/ICO.0000000000000198","volume":"33","author":"Agarwal S.","year":"2014","unstructured":"Agarwal S.; Angayarkanni N.; Iyer G.; Clinico-biochemical correlation of the effect of subconjunctival bevacizumab for corneal neovascularization. Cornea 2014,33(10),1016-1021","journal-title":"Cornea"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.jtos.2018.06.004","volume":"16","author":"Roshandel D.","year":"2018","unstructured":"Roshandel D.; Eslani M.; Baradaran-Rafii A.; Current and emerging therapies for corneal neovascularization. Ocul Surf 2018,16(4),398-414","journal-title":"Ocul Surf"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0039-6257(98)00035-6","volume":"43","author":"Lee P.","year":"1998","unstructured":"Lee P.; Wang C.C.; Adamis A.P.; Ocular neovascularization: an epidemiologic review. Surv Ophthalmol 1998,43(3),245-269","journal-title":"Surv Ophthalmol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/08820530902802013","volume":"24","author":"Lim M.","year":"2009","unstructured":"Lim M.; Jacobs D.S.; Rosenthal P.; Carrasquillo K.G.; The Boston Ocular Surface Prosthesis as a novel drug delivery system for bevacizumab. Semin Ophthalmol 2009,24(3),149-155","journal-title":"Semin Ophthalmol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"195","DOI":"10.5483\/BMBRep.2013.46.4.193","volume":"46","author":"Lee K.J.","year":"2013","unstructured":"Lee K.J.; Lee J.Y.; Lee S.H.; Choi T.H.; Accelerating repaired basement membrane after bevacizumab treatment on alkali-burned mouse cornea. BMB Rep 2013,46(4),195-200","journal-title":"BMB Rep"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/emm.2006.21","volume":"38","author":"Kwon Y.S.","year":"2006","unstructured":"Kwon Y.S.; Kim J.C.; Inhibition of corneal neovascularization by rapamycin. Exp Mol Med 2006,38(2),173-179","journal-title":"Exp Mol Med"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1001\/archopht.1992.01080150103037","volume":"110","author":"Lipman R.M.","year":"1992","unstructured":"Lipman R.M.; Epstein R.J.; Hendricks R.L.; Suppression of corneal neovascularization with cyclosporine. Arch Ophthalmol 1992,110(3),405-407","journal-title":"Arch Ophthalmol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2174\/187221309789257450","volume":"3","author":"Shakiba Y.","year":"2009","unstructured":"Shakiba Y.; Mansouri K.; Arshadi D.; Rezaei N.; Corneal neovascularization: molecular events and therapeutic options. Recent Pat Inflamm Allergy Drug Discov 2009,3(3),221-231","journal-title":"Recent Pat Inflamm Allergy Drug Discov"},{"key":"ref=13","first-page":"18","volume":"39","author":"Amano S.","year":"1998","unstructured":"Amano S.; Rohan R.; Kuroki M.; Tolentino M.; Adamis A.P.; Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci 1998,39(1),18-22","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1001\/archopht.1996.01100140172010","volume":"114","author":"Tolentino M.J.","year":"1996","unstructured":"Tolentino M.J.; Miller J.W.; Gragoudas E.S.; Chatzistefanou K.; Ferrara N.; Adamis A.P.; Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol 1996,114(8),964-970","journal-title":"Arch Ophthalmol"},{"key":"ref=15","first-page":"361","volume":"19","author":"Rosenfeld P.J.","year":"2006","unstructured":"Rosenfeld P.J.; Rich R.M.; Lalwani G.A.; Ranibizumab: Phase III clinical trial results. Ophthalmol Clin North Am 2006,19(3),361-372","journal-title":"Ophthalmol Clin North Am"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1136\/bjo.2007.132597","volume":"92","author":"Singerman L.J.","year":"2008","unstructured":"Singerman L.J.; Masonson H.; Patel M.; Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. Br J Ophthalmol 2008,92(12),1606-1611","journal-title":"Br J Ophthalmol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/ICO.0b013e31821dd986","volume":"31","author":"Tshionyi M.","year":"2012","unstructured":"Tshionyi M.; Shay E.; Lunde E.; Hemangiogenesis and lymphangiogenesis in corneal pathology. Cornea 2012,31(1),74-80","journal-title":"Cornea"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/S1542-0124(11)70035-0","volume":"9","author":"Keating A.M.","year":"2011","unstructured":"Keating A.M.; Jacobs D.S.; Anti-VEGF Treatment of Corneal Neovascularization. Ocul Surf 2011,9(4),227-237","journal-title":"Ocul Surf"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1172\/JCI20465","volume":"113","author":"Cursiefen C.","year":"2004","unstructured":"Cursiefen C.; Chen L.; Borges L.P.; VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest 2004,113(7),1040-1050","journal-title":"J Clin Invest"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1002\/jlb.55.3.410","volume":"55","author":"Sunderk\u00f6tter C.","year":"1994","unstructured":"Sunderk\u00f6tter C.; Steinbrink K.; Goebeler M.; Bhardwaj R.; Sorg C.; Macrophages and angiogenesis. J Leukoc Biol 1994,55(3),410-422","journal-title":"J Leukoc Biol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1006\/exer.1999.0790","volume":"70","author":"Kvanta A.","year":"2000","unstructured":"Kvanta A.; Sarman S.; Fagerholm P.; Seregard S.; Steen B.; Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization. Exp Eye Res 2000,70(4),419-428","journal-title":"Exp Eye Res"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.2353\/ajpath.2007.070172","volume":"171","author":"Nakao S.","year":"2007","unstructured":"Nakao S.; Hata Y.; Miura M.; Dexamethasone inhibits interleukin-1beta-induced corneal neovascularization: role of nuclear factor-kappaB-activated stromal cells in inflammatory angiogenesis. Am J Pathol 2007,171(3),1058-1065","journal-title":"Am J Pathol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.exer.2005.05.001","volume":"82","author":"Biswas P.S.","year":"2006","unstructured":"Biswas P.S.; Banerjee K.; Kinchington P.R.; Rouse B.T.; Involvement of IL-6 in the paracrine production of VEGF in ocular HSV-1 infection. Exp Eye Res 2006,82(1),46-54","journal-title":"Exp Eye Res"},{"key":"ref=24","first-page":"1279","volume":"141","author":"Strieter R.M.","year":"1992","unstructured":"Strieter R.M.; Kunkel S.L.; Elner V.M.; Interleukin-8. A corneal factor that induces neovascularization. Am J Pathol 1992,141(6),1279-1284","journal-title":"Am J Pathol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"3653","DOI":"10.4049\/jimmunol.1003239","volume":"186","author":"Suryawanshi A.","year":"2011","unstructured":"Suryawanshi A.; Mulik S.; Sharma S.; Reddy P.B.; Sehrawat S.; Rouse B.T.; Ocular neovascularization caused by herpes simplex virus type 1 infection results from breakdown of binding between vascular endothelial growth factor A and its soluble receptor. J Immunol 2011,186(6),3653-3665","journal-title":"J Immunol"},{"key":"ref=26","first-page":"2514","volume":"41","author":"Philipp W.","year":"2000","unstructured":"Philipp W.; Speicher L.; Humpel C.; Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci 2000,41(9),2514-2522","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.jcjo.2017.03.017","volume":"52","author":"Termote K.","year":"2017","unstructured":"Termote K.; Schendel S.; Moloney G.; Holland S.P.; Lange A.P.; Focal limbal stem cell deficiency associated with soft contact lens wear. Can J Ophthalmol 2017,52(6),552-558","journal-title":"Can J Ophthalmol"},{"key":"ref=28","first-page":"903","volume":"287","author":"Vafeas C.","year":"1998","unstructured":"Vafeas C.; Mieyal P.A.; Urbano F.; Hypoxia stimulates the synthesis of cytochrome P450-derived inflammatory eicosanoids in rabbit corneal epithelium. J Pharmacol Exp Ther 1998,287(3),903-910","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1167\/iovs.11-8379","volume":"54","author":"Ferrari G.","year":"2013","unstructured":"Ferrari G.; Hajrasouliha A.R.; Sadrai Z.; Ueno H.; Chauhan S.K.; Dana R.; Nerves and neovessels inhibit each other in the cornea. Invest Ophthalmol Vis Sci 2013,54(1),813-820","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/j.1442-9071.2007.01572.x","volume":"35","author":"Hosseini H.","year":"2007","unstructured":"Hosseini H.; Nejabat M.; Mehryar M.; Yazdchi T.; Sedaghat A.; Noori F.; Bevacizumab inhibits corneal neovascularization in an alkali burn induced model of corneal angiogenesis. Clin Exp Ophthalmol 2007,35(8),745-748","journal-title":"Clin Exp Ophthalmol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1167\/iovs.16-19420","volume":"57","author":"Han K.Y.","year":"2016","unstructured":"Han K.Y.; Chang J.H.; Lee H.; Azar D.T.; Proangiogenic Interactions of Vascular Endothelial MMP14 With VEGF Receptor 1 in VEGFA-Mediated Corneal Angiogenesis. Invest Ophthalmol Vis Sci 2016,57(7),3313-3322","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1096\/fasebj.13.1.9","volume":"13","author":"Neufeld G.","year":"1999","unstructured":"Neufeld G.; Cohen T.; Gengrinovitch S.; Poltorak Z.; Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999,13(1),9-22","journal-title":"FASEB J"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/jb\/mvs136","volume":"153","author":"Shibuya M.","year":"2013","unstructured":"Shibuya M.; Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. J Biochem 2013,153(1),13-19","journal-title":"J Biochem"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.2174\/138955709788922665","volume":"9","author":"Klettner A.","year":"2009","unstructured":"Klettner A.; Roider J.; Treating age-related macular degeneration - interaction of VEGF-antagonists with their target. Mini Rev Med Chem 2009,9(9),1127-1135","journal-title":"Mini Rev Med Chem"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"S113","DOI":"10.1046\/j.1523-1755.2000.07718.x","volume":"77","author":"Aiello L.P.","year":"2000","unstructured":"Aiello L.P.; Wong J.S.; Role of vascular endothelial growth factor in diabetic vascular complications. Kidney Int Suppl 2000,77,S113-S119","journal-title":"Kidney Int Suppl"},{"key":"ref=36","first-page":"1029","volume":"146","author":"Dvorak H.F.","year":"1995","unstructured":"Dvorak H.F.; Brown L.F.; Detmar M.; Dvorak A.M.; Vascular permeability factor\/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995,146(5),1029-1039","journal-title":"Am J Pathol"},{"key":"ref=37","first-page":"637","volume":"34","author":"Hoppenreijs V.P.","year":"1993","unstructured":"Hoppenreijs V.P.; Pels E.; Vrensen G.F.; Felten P.C.; Treffers W.F.; Platelet-derived growth factor: receptor expression in corneas and effects on corneal cells. Invest Ophthalmol Vis Sci 1993,34(3),637-649","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1167\/iovs.05-1071","volume":"47","author":"Dell S.","year":"2006","unstructured":"Dell S.; Peters S.; M\u00fcther P.; Kociok N.; Joussen A.M.; The role of PDGF receptor inhibitors and PI3-kinase signaling in the pathogenesis of corneal neovascularization. Invest Ophthalmol Vis Sci 2006,47(5),1928-1937","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=39","first-page":"323","volume":"31","author":"Soubrane G.","year":"1990","unstructured":"Soubrane G.; Jerdan J.; Karpouzas I.; Binding of basic fibroblast growth factor to normal and neovascularized rabbit cornea. Invest Ophthalmol Vis Sci 1990,31(2),323-333","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0065-230X(08)61024-6","volume":"78","author":"Mignatti P.","year":"2000","unstructured":"Mignatti P.; Rifkin D.B.; Nonenzymatic interactions between proteinases and the cell surface: novel roles in normal and malignant cell physiology. Adv Cancer Res 2000,78,103-157","journal-title":"Adv Cancer Res"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"3131","DOI":"10.1172\/JCI119868","volume":"100","author":"Papapetropoulos A.","year":"1997","unstructured":"Papapetropoulos A.; Garc\u00eda-Carde\u00f1a G.; Madri J.A.; Sessa W.C.; Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 1997,100(12),3131-3139","journal-title":"J Clin Invest"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.1096\/fj.09-145102","volume":"24","author":"Bryan B.A.","year":"2010","unstructured":"Bryan B.A.; Dennstedt E.; Mitchell D.C.; RhoA\/ROCK signaling is essential for multiple aspects of VEGF-mediated angiogenesis. FASEB J 2010,24(9),3186-3195","journal-title":"FASEB J"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1161\/ATVBAHA.114.304627","volume":"35","author":"Wang Z.","year":"2015","unstructured":"Wang Z.; Cheng R.; Lee K.; Nanoparticle-mediated expression of a Wnt pathway inhibitor ameliorates ocular neovascularization. Arterioscler Thromb Vasc Biol 2015,35(4),855-864","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1097\/ICO.0b013e3182781ea4","volume":"32","author":"Kim S.J.","year":"2013","unstructured":"Kim S.J.; Lee J.W.; Yeo E.D.; The role of Nod1 signaling in corneal neovascularization. Cornea 2013,32(5),674-679","journal-title":"Cornea"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.ajo.2005.05.020","volume":"140","author":"Al-Torbak A.","year":"2005","unstructured":"Al-Torbak A.; Al-Amri A.; Wagoner M.D.; Deep corneal neovascularization after implantation with intrastromal corneal ring segments. Am J Ophthalmol 2005,140(5),926-927","journal-title":"Am J Ophthalmol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.exer.2016.04.016","volume":"147","author":"Cejkova J.","year":"2016","unstructured":"Cejkova J.; Cejka C.; Trosan P.; Zajicova A.; Sykova E.; Holan V.; Treatment of alkali-injured cornea by cyclosporine A-loaded electrospun nanofibers - An alternative mode of therapy. Exp Eye Res 2016,147,128-137","journal-title":"Exp Eye Res"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1097\/ICO.0000000000000336","volume":"34","author":"Park J.H.","year":"2015","unstructured":"Park J.H.; Joo C.K.; Chung S.K.; Comparative study of tacrolimus and bevacizumab on corneal neovascularization in rabbits. Cornea 2015,34(4),449-455","journal-title":"Cornea"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0161-6420(92)31996-7","volume":"99","author":"Baer J.C.","year":"1992","unstructured":"Baer J.C.; Foster C.S.; Corneal laser photocoagulation for treatment of neovascularization. Efficacy of 577 nm yellow dye laser. Ophthalmology 1992,99(2),173-179","journal-title":"Ophthalmology"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1136\/bjo.2003.035071","volume":"88","author":"Brooks B.J.","year":"2004","unstructured":"Brooks B.J.; Ambati B.K.; Marcus D.M.; Ratanasit A.; Photodynamic therapy for corneal neovascularisation and lipid degeneration. Br J Ophthalmol 2004,88(6),840","journal-title":"Br J Ophthalmol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/j.1600-0420.2007.01049.x","volume":"86","author":"Yoeruek E.","year":"2008","unstructured":"Yoeruek E.; Ziemssen F.; Henke-Fahle S.; Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn. Acta Ophthalmol T\u00fcbingen Bevacizumab Study Group2008,86(3),322-328","journal-title":"Acta Ophthalmol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1111\/j.1755-3768.2008.01399.x","volume":"87","author":"You I.C.","year":"2009","unstructured":"You I.C.; Kang I.S.; Lee S.H.; Yoon K.C.; Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization. Acta Ophthalmol 2009,87(6),653-658","journal-title":"Acta Ophthalmol"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"311","DOI":"10.5114\/ceji.2016.63132","volume":"41","author":"Po\u017carowska D.","year":"2016","unstructured":"Po\u017carowska D.; Po\u017carowski P.; The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy. Cent Eur J Immunol 2016,41(3),311-316","journal-title":"Cent Eur J Immunol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1097\/ICU.0b013e3282f0ca54","volume":"18","author":"Andreoli C.M.","year":"2007","unstructured":"Andreoli C.M.; Miller J.W.; Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol 2007,18(6),502-508","journal-title":"Curr Opin Ophthalmol"},{"key":"ref=54","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/852183","author":"Kimoto K.","year":"2012","unstructured":"Kimoto K.; Kubota T.; Anti-VEGF agents for ocular angiogenesis and vascular permeability. J Ophthalmol 2012","journal-title":"J Ophthalmol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.survophthal.2012.01.007","volume":"57","author":"Chang J.H.","year":"2012","unstructured":"Chang J.H.; Garg N.K.; Lunde E.; Han K.Y.; Jain S.; Azar D.T.; Corneal neovascularization: an anti-VEGF therapy review. Surv Ophthalmol 2012,57(5),415-429","journal-title":"Surv Ophthalmol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1517\/14712598.2012.721772","volume":"12","author":"Park S.C.","year":"2012","unstructured":"Park S.C.; Su D.; Tello C.; Anti-VEGF therapy for the treatment of glaucoma: a focus on ranibizumab and bevacizumab. Expert Opin Biol Ther 2012,12(12),1641-1647","journal-title":"Expert Opin Biol Ther"},{"key":"ref=57","first-page":"8","volume":"8","author":"Popescu V.","year":"2015","unstructured":"Popescu V.; Pricopie S.; Totir M.; Iancu R.; Yasyn S.; Alexandrescu C.; Clinical use of Bevacizumab in treating refractory glaucoma. J Med Life 2015,8(1),8-12","journal-title":"J Med Life"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1177\/1947601911423031","volume":"2","author":"Shibuya M.","year":"2011","unstructured":"Shibuya M.; Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies. Genes Cancer 2011,2(12),1097-1105","journal-title":"Genes Cancer"},{"key":"ref=59","first-page":"S85","volume":"19","author":"Cardarelli W.J.","year":"2013","unstructured":"Cardarelli W.J.; Smith R.A.; Managed care implications of age-related ocular conditions. Am J Manag Care 2013,19(5)(Suppl.),S85-S91","journal-title":"Am J Manag Care"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1159\/000431199","volume":"55","author":"Klein A.","year":"2016","unstructured":"Klein A.; Loewenstein A.; Therapeutic monoclonal antibodies and fragments: Bevacizumab. Dev Ophthalmol 2016,55,232-245","journal-title":"Dev Ophthalmol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/eye.2014.13","volume":"28","author":"Osaadon P.","year":"2014","unstructured":"Osaadon P.; Fagan X.J.; Lifshitz T.; Levy J.; A review of anti-VEGF agents for proliferative diabetic retinopathy. Eye (Lond) 2014,28(5),510-520","journal-title":"Eye (Lond)"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3341\/kjo.2014.28.2.177","volume":"28","author":"Ahn Y.J.","year":"2014","unstructured":"Ahn Y.J.; Hwang H.B.; Chung S.K.; Ranibizumab injection for corneal neovascularization refractory to bevacizumab treatment. Korean J Ophthalmol 2014,28(2),177-180","journal-title":"Korean J Ophthalmol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jtos.2012.01.005","volume":"10","author":"Stevenson W.","year":"2012","unstructured":"Stevenson W.; Cheng S.F.; Dastjerdi M.H.; Ferrari G.; Dana R.; Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin). Ocul Surf 2012,10(2),67-83","journal-title":"Ocul Surf"},{"key":"ref=64","first-page":"387","volume":"6","author":"Ferrari G.","year":"2015","unstructured":"Ferrari G.; Giacomini C.; Rama P.; Corneal neovascularization: A translational perspective. J Clin Exp Ophthalmol 2015,6,387-395","journal-title":"J Clin Exp Ophthalmol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1136\/bjo.2007.134874","volume":"92","author":"Stewart M.W.","year":"2008","unstructured":"Stewart M.W.; Rosenfeld P.J.; Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol 2008,92(5),667-668","journal-title":"Br J Ophthalmol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1472-6750-14-17","volume":"14","author":"Wang Q.","year":"2014","unstructured":"Wang Q.; Yang J.; Tang K.; Pharmacological characteristics and efficacy of a novel anti-angiogenic antibody FD006 in corneal neovascularization. BMC Biotechnol 2014,14(1),17","journal-title":"BMC Biotechnol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"4242","DOI":"10.1182\/blood-2012-08-453043","volume":"121","author":"Singh N.","year":"2013","unstructured":"Singh N.; Tiem M.; Watkins R.; Soluble vascular endothelial growth factor receptor 3 is essential for corneal alymphaticity. Blood 2013,121(20),4242-4249","journal-title":"Blood"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1097\/ICO.0b013e318206c893","volume":"30","author":"Iriyama A.","year":"2011","unstructured":"Iriyama A.; Usui T.; Yanagi Y.; Gene transfer using micellar nanovectors inhibits corneal neovascularization in vivo. Cornea 2011,30(12),1423-1427","journal-title":"Cornea"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"8458","DOI":"10.1167\/iovs.12-10408","volume":"53","author":"Cho Y.K.","year":"2012","unstructured":"Cho Y.K.; Zhang X.; Uehara H.; Young J.R.; Archer B.; Ambati B.; Vascular Endothelial Growth Factor Receptor 1 morpholino increases graft survival in a murine penetrating keratoplasty model. Invest Ophthalmol Vis Sci 2012,53(13),8458-8471","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1167\/iovs.06-0853","volume":"48","author":"Jani P.D.","year":"2007","unstructured":"Jani P.D.; Singh N.; Jenkins C.; Nanoparticles sustain expression of Flt intraceptors in the cornea and inhibit injury-induced corneal angiogenesis. Invest Ophthalmol Vis Sci 2007,48(5),2030-2036","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=71","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a006411","volume":"2","author":"Al-Latayfeh M.","year":"2012","unstructured":"Al-Latayfeh M.; Silva P.S.; Sun J.K.; Aiello L.P.; Antiangiogenic therapy for ischemic retinopathies. Cold Spring Harb Perspect Med 2012,2(6)","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/jcp.22251","volume":"225","author":"Ahmad S.","year":"2010","unstructured":"Ahmad S.; Osei-Bempong C.; Dana R.; Jurkunas U.; The culture and transplantation of human limbal stem cells. J Cell Physiol 2010,225(1),15-19","journal-title":"J Cell Physiol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/bies.201200086","volume":"35","author":"Osei-Bempong C.","year":"2013","unstructured":"Osei-Bempong C.; Figueiredo F.C.; Lako M.; The limbal epithelium of the eye--a review of limbal stem cell biology, disease and treatment. BioEssays 2013,35(3),211-219","journal-title":"BioEssays"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1097\/ICO.0b013e31822480f9","volume":"31","author":"Hosseini H.","year":"2012","unstructured":"Hosseini H.; Nowroozzadeh M.H.; Salouti R.; Nejabat M.; Anti-VEGF therapy with bevacizumab for anterior segment eye disease. Cornea 2012,31(3),322-334","journal-title":"Cornea"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"83","DOI":"10.4103\/0974-620X.116624","volume":"6","author":"Singh P.","year":"2013","unstructured":"Singh P.; Tyagi M.; Kumar Y.; Gupta K.K.; Sharma P.D.; Ocular chemical injuries and their management. Oman J Ophthalmol 2013,6(2),83-86","journal-title":"Oman J Ophthalmol"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1136\/bjo.2006.107912","volume":"91","author":"Manzano R.P.","year":"2007","unstructured":"Manzano R.P.; Peyman G.A.; Khan P.; Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin). Br J Ophthalmol 2007,91(6),804-807","journal-title":"Br J Ophthalmol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1590\/S0001-37652007000300004","volume":"79","author":"Barros L.F.","year":"2007","unstructured":"Barros L.F.; Belfort R.; The effects of the subconjunctival injection of bevacizumab (Avastin) on angiogenesis in the rat cornea. An Acad Bras Cienc 2007,79(3),389-394","journal-title":"An Acad Bras Cienc"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/02713680802607740","volume":"34","author":"Oh J.Y.","year":"2009","unstructured":"Oh J.Y.; Kim M.K.; Shin M.S.; Lee H.J.; Lee J.H.; Wee W.R.; The anti-inflammatory effect of subconjunctival bevacizumab on chemically burned rat corneas. Curr Eye Res 2009,34(2),85-91","journal-title":"Curr Eye Res"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.burns.2012.07.018","volume":"39","author":"Doganay S.","year":"2013","unstructured":"Doganay S.; Firat P.G.; Cankaya C.; Kirimlioglu H.; Evaluation of the effects of resveratrol and bevacizumab on experimental corneal alkali burn. Burns 2013,39(2),326-330","journal-title":"Burns"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/archopht.125.6.834","volume":"125","author":"DeStafeno J.J.","year":"2007","unstructured":"DeStafeno J.J.; Kim T.; Topical bevacizumab therapy for corneal neovascularization. Arch Ophthalmol 2007,125(6),834-836","journal-title":"Arch Ophthalmol"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1097\/ICO.0b013e318159019f","volume":"27","author":"Bahar I.","year":"2008","unstructured":"Bahar I.; Kaiserman I.; McAllum P.; Rootman D.; Slomovic A.; Subconjunctival bevacizumab injection for corneal neovascularization. Cornea 2008,27(2),142-147","journal-title":"Cornea"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.ophtha.2005.11.019","volume":"113","author":"Avery R.L.","year":"2006","unstructured":"Avery R.L.; Pieramici D.J.; Rabena M.D.; Castellarin A.A.; Nasir M.A.; Giust M.J.; Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006,113(3),363-372.e5","journal-title":"Ophthalmology"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1136\/bjo.2005.066431","volume":"89","author":"Nguyen Q.D.","year":"2005","unstructured":"Nguyen Q.D.; Shah S.; Tatlipinar S.; Do D.V.; Anden E.V.; Campochiaro P.A.; Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia. Br J Ophthalmol 2005,89(10),1368-1370","journal-title":"Br J Ophthalmol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.ophtha.2005.01.043","volume":"112","author":"Rosenfeld P.J.","year":"2005","unstructured":"Rosenfeld P.J.; Schwartz S.D.; Blumenkranz M.S.; Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 2005,112(6),1048-1053","journal-title":"Ophthalmology"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s00417-007-0684-4","volume":"246","author":"Bock F.","year":"2008","unstructured":"Bock F.; K\u00f6nig Y.; Kruse F.; Baier M.; Cursiefen C.; Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2008,246(2),281-284","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1097\/01.ico.0000157400.81408.2b","volume":"24","author":"Kuhlmann A.","year":"2005","unstructured":"Kuhlmann A.; Amann K.; Schl\u00f6tzer-Schrehardt U.; Kruse F.E.; Cursiefen C.; Endothelin-1 and ETA\/ETB receptor protein and mRNA: expression in normal and vascularized human corneas. Cornea 2005,24(7),837-844","journal-title":"Cornea"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1080\/092739490500363","volume":"12","author":"Remeijer L.","year":"2004","unstructured":"Remeijer L.; Osterhaus A.; Verjans G.; Human herpes simplex virus keratitis: the pathogenesis revisited. Ocul Immunol Inflamm 2004,12(4),255-285","journal-title":"Ocul Immunol Inflamm"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2147\/OPTH.S1858","volume":"2","author":"Hayashi T.","year":"2008","unstructured":"Hayashi T.; Ishioka M.; Ito N.; Bilateral herpes simplex keratitis in a patient with chronic graft-versus-host disease. Clin Ophthalmol 2008,2(2),457-459","journal-title":"Clin Ophthalmol"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S0002-9440(10)61777-4","volume":"159","author":"Zheng M.","year":"2001","unstructured":"Zheng M.; Schwarz M.A.; Lee S.; Kumaraguru U.; Rouse B.T.; Control of stromal keratitis by inhibition of neovascularization. Am J Pathol 2001,159(3),1021-1029","journal-title":"Am J Pathol"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1097\/ICO.0b013e31823f8d71","volume":"31","author":"Benayoun Y.","year":"2012","unstructured":"Benayoun Y.; Adenis J.P.; Casse G.; Forte R.; Robert P.Y.; Effects of subconjunctival bevacizumab on corneal neovascularization: results of a prospective study. Cornea 2012,31(8),937-944","journal-title":"Cornea"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1136\/bjophthalmol-2012-302137","volume":"97","author":"Petsoglou C.","year":"2013","unstructured":"Petsoglou C.; Balaggan K.S.; Dart J.K.G.; Subconjunctival bevacizumab induces regression of corneal neovascularisation: a pilot randomised placebo-controlled double-masked trial. Br J Ophthalmol 2013,97(1),28-32","journal-title":"Br J Ophthalmol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1097\/01.ico.0000611440.32234.8f","volume":"27","author":"Carrasco M.A.","year":"2008","unstructured":"Carrasco M.A.; Subconjunctival bevacizumab for corneal neovascularization in herpetic stromal keratitis. Cornea 2008,27(6),743-745","journal-title":"Cornea"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1097\/ICO.0b013e3181dc81a0","volume":"30","author":"You I.C.","year":"2011","unstructured":"You I.C.; Im S.K.; Lee S.H.; Yoon K.C.; Photodynamic therapy with verteporfin combined with subconjunctival injection of bevacizumab for corneal neovascularization. Cornea 2011,30(1),30-33","journal-title":"Cornea"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s00417-009-1099-1","volume":"247","author":"Koenig Y.","year":"2009","unstructured":"Koenig Y.; Bock F.; Horn F.; Kruse F.; Straub K.; Cursiefen C.; Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2009,247(10),1375-1382","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1097\/ICO.0b013e31821379aa","volume":"30","author":"Yeung S.N.","year":"2011","unstructured":"Yeung S.N.; Lichtinger A.; Kim P.; Amiran M.D.; Slomovic A.R.; Combined use of subconjunctival and intracorneal bevacizumab injection for corneal neovascularization. Cornea 2011,30(10),1110-1114","journal-title":"Cornea"},{"key":"ref=96","first-page":"2034","volume":"24","author":"Pleyer U.","year":"1992","unstructured":"Pleyer U.; Steuhl K.P.; Weidle E.G.; Lisch W.; Thiel H.J.; Corneal graft rejection: incidence, manifestation, and interaction of clinical subtypes. Transplant Proc 1992,24(5),2034-2037","journal-title":"Transplant Proc"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1001\/archopht.121.8.1087","volume":"121","author":"Price M.O.","year":"2003","unstructured":"Price M.O.; Thompson R.W.; Price F.W.; Risk factors for various causes of failure in initial corneal grafts. Arch Ophthalmol 2003,121(8),1087-1092","journal-title":"Arch Ophthalmol"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/j.ophtha.2006.12.012","volume":"114","author":"Wagoner M.D.","year":"2007","unstructured":"Wagoner M.D.; Ba-Abbad R.; Sutphin J.E.; Zimmerman M.B.; Corneal transplant survival after onset of severe endothelial rejection. Ophthalmology 2007,114(9),1630-1636","journal-title":"Ophthalmology"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1167\/iovs.06-0570","volume":"48","author":"Bock F.","year":"2007","unstructured":"Bock F.; Onderka J.; Dietrich T.; Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 2007,48(6),2545-2552","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=100","first-page":"2127","volume":"43","author":"Cursiefen C.","year":"2002","unstructured":"Cursiefen C.; Schl\u00f6tzer-Schrehardt U.; K\u00fcchle M.; Lymphatic vessels in vascularized human corneas: immunohistochemical investigation using LYVE-1 and podoplanin. Invest Ophthalmol Vis Sci 2002,43(7),2127-2135","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1007\/s00417-014-2626-2","volume":"252","author":"Lipp M.","year":"2014","unstructured":"Lipp M.; Bucher F.; Parthasarathy A.; Blockade of the VEGF isoforms in inflammatory corneal hemangiogenesis and lymphangiogenesis. Graefes Arch Clin Exp Ophthalmol 2014,252(6),943-949","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1089\/jop.2015.0007","volume":"31","author":"Yan H.","year":"2015","unstructured":"Yan H.; Yuan J.; Peng R.; The Blockade of Vascular Endothelial Growth Factor C Effectively Inhibits Corneal Lymphangiogenesis and Promotes Allograft Survival. J Ocul Pharmacol Ther 2015,31(9),546-554","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.survophthal.2014.06.001","volume":"60","author":"Park P.J.","year":"2015","unstructured":"Park P.J.; Chang M.; Garg N.; Zhu J.; Chang J.H.; Shukla D.; Corneal lymphangiogenesis in herpetic stromal keratitis. Surv Ophthalmol 2015,60(1),60-71","journal-title":"Surv Ophthalmol"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1016\/j.ophtha.2007.05.016","volume":"114","author":"Harooni H.","year":"2007","unstructured":"Harooni H.; Reddy V.; Root T.; Ambati B.; Bevacizumab for graft rejection. Ophthalmology 2007,114(10),1950","journal-title":"Ophthalmology"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s00417-007-0587-4","volume":"245","author":"Erdurmus M.","year":"2007","unstructured":"Erdurmus M.; Totan Y.; Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2007,245(10),1577-1579","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1016\/j.jcrs.2007.07.012","volume":"33","author":"Awadein A.","year":"2007","unstructured":"Awadein A.; Subconjunctival bevacizumab for vascularized rejected corneal grafts. J Cataract Refract Surg 2007,33(11),1991-1993","journal-title":"J Cataract Refract Surg"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1615\/CritRevImmunol.v18.i4.20","volume":"18","author":"Rocha G.","year":"1998","unstructured":"Rocha G.; Desch\u00eanes J.; Rowsey J.J.; The immunology of corneal graft rejection. Crit Rev Immunol 1998,18(4),305-325","journal-title":"Crit Rev Immunol"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10792-014-9938-4","volume":"35","author":"Fasciani R.","year":"2015","unstructured":"Fasciani R.; Mosca L.; Giannico M.I.; Ambrogio S.A.; Balestrazzi E.; Subconjunctival and\/or intrastromal bevacizumab injections as preconditioning therapy to promote corneal graft survival. Int Ophthalmol 2015,35(2),221-227","journal-title":"Int Ophthalmol"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1097\/ICO.0b013e3180318107","volume":"26","author":"Niederer R.L.","year":"2007","unstructured":"Niederer R.L.; Sherwin T.; McGhee C.N.J.; In vivo confocal microscopy of subepithelial infiltrates in human corneal transplant rejection. Cornea 2007,26(4),501-504","journal-title":"Cornea"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/ICO.0b013e31820ca19e","volume":"31","author":"Jarr\u00edn E.","year":"2012","unstructured":"Jarr\u00edn E.; Ruiz-Casas D.; Mendivil A.; Efficacy of bevacizumab against interface neovascularization after deep anterior lamellar keratoplasty. Cornea 2012,31(2),188-190","journal-title":"Cornea"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/ICO.0b013e3181e291a6","volume":"30","author":"Hashemian M.N.","year":"2011","unstructured":"Hashemian M.N.; Zare M.A.; Rahimi F.; Mohammadpour M.; Deep intrastromal bevacizumab injection for management of corneal stromal vascularization after deep anterior lamellar keratoplasty, a novel technique. Cornea 2011,30(2),215-218","journal-title":"Cornea"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1177\/112067210901900530","volume":"19","author":"Saxena S.","year":"2009","unstructured":"Saxena S.; Kishore P.; Pandey S.; Khattri M.; Kumar D.; Topical bevacizumab for corneal neovascularization after penetrating keratoplasty. Eur J Ophthalmol 2009,19(5),870-872","journal-title":"Eur J Ophthalmol"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ajo.2016.03.020","volume":"166","author":"Catt C.J.","year":"2016","unstructured":"Catt C.J.; Hamilton G.M.; Fish J.; Mireskandari K.; Ali A.; Ocular Manifestations of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Children. Am J Ophthalmol 2016,166,68-75","journal-title":"Am J Ophthalmol"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1167\/iovs.03-0940","volume":"45","author":"Cursiefen C.","year":"2004","unstructured":"Cursiefen C.; Masli S.; Ng T.F.; Roles of thrombospondin-1 and -2 in regulating corneal and iris angiogenesis. Invest Ophthalmol Vis Sci 2004,45(4),1117-1124","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1001\/archopht.1983.01040010640024","volume":"101","author":"Phillips K.","year":"1983","unstructured":"Phillips K.; Arffa R.; Cintron C.; Effects of prednisolone and medroxyprogesterone on corneal wound healing, ulceration, and neovascularization. Arch Ophthalmol 1983,101(4),640-643","journal-title":"Arch Ophthalmol"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1001\/archopht.120.8.1063","volume":"120","author":"Ambati B.K.","year":"2002","unstructured":"Ambati B.K.; Joussen A.M.; Ambati J.; Angiostatin inhibits and regresses corneal neovascularization. Arch Ophthalmol 2002,120(8),1063-1068","journal-title":"Arch Ophthalmol"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1001\/archopht.1989.01070020575043","volume":"107","author":"Corrent G.","year":"1989","unstructured":"Corrent G.; Roussel T.J.; Tseng S.C.G.; Watson B.D.; Promotion of graft survival by photothrombotic occlusion of corneal neovascularization. Arch Ophthalmol 1989,107(10),1501-1506","journal-title":"Arch Ophthalmol"},{"key":"ref=118","first-page":"2148","volume":"41","author":"Pillai C.T.","year":"2000","unstructured":"Pillai C.T.; Dua H.S.; Hossain P.; Fine needle diathermy occlusion of corneal vessels. Invest Ophthalmol Vis Sci 2000,41(8),2148-2153","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1097\/ICO.0b013e31817c41e3","volume":"27","author":"Qian C.X.","year":"2008","unstructured":"Qian C.X.; Bahar I.; Levinger E.; Rootman D.; Combined use of superficial keratectomy and subconjunctival bevacizumab injection for corneal neovascularization. Cornea 2008,27(9),1090-1092","journal-title":"Cornea"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/ICO.0b013e318158f6ad","volume":"27","author":"Uy H.S.","year":"2008","unstructured":"Uy H.S.; Chan P.S.; Ang R.E.; Topical bevacizumab and ocular surface neovascularization in patients with stevens-johnson syndrome. Cornea 2008,27(1),70-73","journal-title":"Cornea"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.jaapos.2011.12.153","volume":"16","author":"Kesarwani S.","year":"2012","unstructured":"Kesarwani S.; Sahu S.K.; Basu S.; Bilateral response after unilateral subconjunctival bevacizumab injection in a child with Stevens-Johnson syndrome. J AAPOS 2012,16(3),309-311","journal-title":"J AAPOS"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s10792-017-0786-x","volume":"39","author":"Yoon H.J.","year":"2019","unstructured":"Yoon H.J.; Kim M.K.; Seo K.Y.; Ueta M.; Yoon K.C.; Effectiveness of photodynamic therapy with verteporfin combined with intrastromal bevacizumab for corneal neovascularization in Stevens-Johnson syndrome. Int Ophthalmol 2019,39(1),55-62","journal-title":"Int Ophthalmol"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1089\/jop.2009.0022","volume":"26","author":"Kim M.J.","year":"2010","unstructured":"Kim M.J.; Han E.S.; Kim J.; Kim T.W.; Aqueous humor concentration of bevacizumab after subconjunctival injection in rabbit. J Ocul Pharmacol Ther 2010,26(1),49-53","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","volume":"114","author":"Bakri S.J.","year":"2007","unstructured":"Bakri S.J.; Snyder M.R.; Reid J.M.; Pulido J.S.; Singh R.J.; Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007,114(5),855-859","journal-title":"Ophthalmology"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/sj.eye.6701811","volume":"20","author":"Abu El-Asrar A.M.","year":"2006","unstructured":"Abu El-Asrar A.M.; Al-Mansouri S.; Tabbara K.F.; Missotten L.; Geboes K.; Immunopathogenesis of conjunctival remodelling in vernal keratoconjunctivitis. Eye (Lond) 2006,20(1),71-79","journal-title":"Eye (Lond)"},{"key":"ref=126","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/2602487","author":"Nguyen C.L.","year":"2018","unstructured":"Nguyen C.L.; Chen T.S.; Tran K.; Smith J.E.H.; Lewis N.; Simultaneous Subconjunctival Triamcinolone and Bevacizumab Injections for Management of Blepharokeratoconjunctivitis in Children. Case Rep Ophthalmol Med 2018","journal-title":"Case Rep Ophthalmol Med"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1097\/ICO.0000000000000419","volume":"34","author":"Elbaz U.","year":"2015","unstructured":"Elbaz U.; Mireskandari K.; Shen C.; Ali A.; Corneal Fine Needle Diathermy With Adjuvant Bevacizumab to Treat Corneal Neovascularization in Children. Cornea 2015,34(7),773-777","journal-title":"Cornea"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s12026-019-09087-7","volume":"67","author":"Taurone S.","year":"2019","unstructured":"Taurone S.; Spoletini M.; Ralli M.; Ocular mucous membrane pemphigoid: a review. Immunol Res 2019,67(2-3),280-289","journal-title":"Immunol Res"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","volume":"15","author":"Craig J.P.","year":"2017","unstructured":"Craig J.P.; Nichols K.K.; Akpek E.K.; TFOS DEWS II Definition and Classification Report. Ocul Surf 2017,15(3),276-283","journal-title":"Ocul Surf"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3109\/09273941003721926","volume":"18","author":"Calonge M.","year":"2010","unstructured":"Calonge M.; Enr\u00edquez-de-Salamanca A.; Diebold Y.; Dry eye disease as an inflammatory disorder. Ocul Immunol Inflamm 2010,18(4),244-253","journal-title":"Ocul Immunol Inflamm"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"4302","DOI":"10.1167\/iovs.04-0299","volume":"45","author":"Li D.Q.","year":"2004","unstructured":"Li D.Q.; Chen Z.; Song X.J.; Luo L.; Pflugfelder S.C.; Stimulation of matrix metalloproteinases by hyperosmolarity via a JNK pathway in human corneal epithelial cells. Invest Ophthalmol Vis Sci 2004,45(12),4302-4311","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=132","doi-asserted-by":"publisher","DOI":"10.1155\/2008\/129873","author":"Yoo S.A.","year":"2008","unstructured":"Yoo S.A.; Kwok S.K.; Kim W.U.; Proinflammatory role of vascular endothelial growth factor in the pathogenesis of rheumatoid arthritis: prospects for therapeutic intervention. Mediators Inflamm 2008","journal-title":"Mediators Inflamm"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nm0603-669","volume":"9","author":"Ferrara N.","year":"2003","unstructured":"Ferrara N.; Gerber H-P.; LeCouter J.; The biology of VEGF and its receptors. Nat Med 2003,9(6),669-676","journal-title":"Nat Med"},{"key":"ref=134","first-page":"3043","volume":"9","author":"Jiang X.","year":"2015","unstructured":"Jiang X.; Lv H.; Qiu W.; Liu Z.; Li X.; Wang W.; Efficiency and safety of subconjunctival injection of anti-VEGF agent - bevacizumab - in treating dry eye. Drug Des Devel Ther 2015,9,3043-3050","journal-title":"Drug Des Devel Ther"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.2147\/DDDT.S146556","volume":"12","author":"Jiang X.","year":"2018","unstructured":"Jiang X.; Wang Y.; Lv H.; Liu Y.; Zhang M.; Li X.; Efficacy of intra-meibomian gland injection of the anti-VEGF agent bevacizumab for the treatment of meibomian gland dysfunction with lid-margin vascularity. Drug Des Devel Ther 2018,12,1269-1279","journal-title":"Drug Des Devel Ther"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1076\/ceyr.23.1.1.5422","volume":"23","author":"Mastyugin V.","year":"2001","unstructured":"Mastyugin V.; Mosaed S.; Bonazzi A.; Dunn M.W.; Schwartzman M.L.; Corneal epithelial VEGF and cytochrome P450 4B1 expression in a rabbit model of closed eye contact lens wear. Curr Eye Res 2001,23(1),1-10","journal-title":"Curr Eye Res"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/j.1755-3768.2009.01585.x","volume":"88","author":"Zaki A.A.","year":"2010","unstructured":"Zaki A.A.; Farid S.F.; Subconjunctival bevacizumab for corneal neovascularization. Acta Ophthalmol 2010,88(8),868-871","journal-title":"Acta Ophthalmol"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1089\/jop.2010.0094","volume":"27","author":"Banifatemi M.","year":"2011","unstructured":"Banifatemi M.; Razeghinejad M.R.; Hosseini H.; Gholampour A.; Bevacizumab and ocular wound healing after primary pterygium excision. J Ocul Pharmacol Ther 2011,27(1),17-21","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1159\/000252980","volume":"43","author":"Razeghinejad M.R.","year":"2010","unstructured":"Razeghinejad M.R.; Hosseini H.; Ahmadi F.; Rahat F.; Eghbal H.; Preliminary results of subconjunctival bevacizumab in primary pterygium excision. Ophthalmic Res 2010,43(3),134-138","journal-title":"Ophthalmic Res"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1080\/08820530902801106","volume":"24","author":"Mauro J.","year":"2009","unstructured":"Mauro J.; Foster C.S.; Pterygia: pathogenesis and the role of subconjunctival bevacizumab in treatment. Semin Ophthalmol 2009,24(3),130-134","journal-title":"Semin Ophthalmol"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1076\/ceyr.25.1.17.9959","volume":"25","author":"Marcovich A.L.","year":"2002","unstructured":"Marcovich A.L.; Morad Y.; Sandbank J.; Angiogenesis in pterygium: morphometric and immunohistochemical study. Curr Eye Res 2002,25(1),17-22","journal-title":"Curr Eye Res"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00003226-200307000-00015","volume":"22","author":"Jin J.","year":"2003","unstructured":"Jin J.; Guan M.; Sima J.; Decreased pigment epithelium-derived factor and increased vascular endothelial growth factor levels in pterygia. Cornea 2003,22(5),473-477","journal-title":"Cornea"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1097\/00003226-200110000-00013","volume":"20","author":"Lee D.H.","year":"2001","unstructured":"Lee D.H.; Cho H.J.; Kim J.T.; Choi J.S.; Joo C.K.; Expression of vascular endothelial growth factor and inducible nitric oxide synthase in pterygia. Cornea 2001,20(7),738-742","journal-title":"Cornea"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/02713680701799101","volume":"33","author":"Bahar I.","year":"2008","unstructured":"Bahar I.; Kaiserman I.; McAllum P.; Rootman D.; Slomovic A.; Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium. Curr Eye Res 2008,33(1),23-28","journal-title":"Curr Eye Res"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/ceo.12140","volume":"42","author":"Nava-Casta\u00f1eda A.","year":"2014","unstructured":"Nava-Casta\u00f1eda A.; Olvera-Morales O.; Ramos-Castellon C.; Garnica-Hayashi L.; Garfias Y.; Randomized, controlled trial of conjunctival autografting combined with subconjunctival bevacizumab for primary pterygium treatment: 1-year follow-up. Clin Exp Ophthalmol 2014,42(3),235-241","journal-title":"Clin Exp Ophthalmol"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00417-007-0660-z","volume":"246","author":"Wu L.","year":"2008","unstructured":"Wu L.; Mart\u00ednez-Castellanos M.A.; Quiroz-Mercado H.; Pan American Collaborative Retina Group (PACORES). Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008,246(1),81-87","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref=147","first-page":"467","volume":"7","author":"Hurmeric V.","year":"2013","unstructured":"Hurmeric V.; Vaddavalli P.; Galor A.; Perez V.L.; Roman J.S.; Yoo S.H.; Single and multiple injections of subconjunctival ranibizumab for early, recurrent pterygium. Clin Ophthalmol 2013,7,467-473","journal-title":"Clin Ophthalmol"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1016\/j.ophtha.2008.02.013","volume":"115","author":"Kim S.W.","year":"2008","unstructured":"Kim S.W.; Ha B.J.; Kim E.K.; Tchah H.; Kim T.I.; The effect of topical bevacizumab on corneal neovascularization. Ophthalmology 2008,115(6),e33-e38","journal-title":"Ophthalmology"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1097\/ICO.0b013e3182775f8d","volume":"32","author":"Ferrari G.","year":"2013","unstructured":"Ferrari G.; Dastjerdi M.H.; Okanobo A.; Topical ranibizumab as a treatment of corneal neovascularization. Cornea 2013,32(7),992-997","journal-title":"Cornea"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1001\/archophthalmol.2009.18","volume":"127","author":"Dastjerdi M.H.","year":"2009","unstructured":"Dastjerdi M.H.; Al-Arfaj K.M.; Nallasamy N.; Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study. Arch Ophthalmol 2009,127(4),381-389","journal-title":"Arch Ophthalmol"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1167\/iovs.08-1997","volume":"50","author":"Chen W.L.","year":"2009","unstructured":"Chen W.L.; Lin C.T.; Lin N.T.; Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis. Invest Ophthalmol Vis Sci 2009,50(4),1659-1665","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1097\/ICO.0b013e318180e50f","volume":"27","author":"Gerten G.","year":"2008","unstructured":"Gerten G.; Bevacizumab (avastin) and argon laser to treat neovascularization in corneal transplant surgery. Cornea 2008,27(10),1195-1199","journal-title":"Cornea"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1097\/ICO.0b013e31817786ad","volume":"27","author":"Doctor P.P.","year":"2008","unstructured":"Doctor P.P.; Bhat P.V.; Foster C.S.; Subconjunctival bevacizumab for corneal neovascularization. Cornea 2008,27(9),992-995","journal-title":"Cornea"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1167\/iovs.09-3745","volume":"51","author":"Dastjerdi M.H.","year":"2010","unstructured":"Dastjerdi M.H.; Saban D.R.; Okanobo A.; Effects of topical and subconjunctival bevacizumab in high-risk corneal transplant survival. Invest Ophthalmol Vis Sci 2010,51(5),2411-2417","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/j.1442-9071.2009.02112.x","volume":"37","author":"Ahmed A.","year":"2009","unstructured":"Ahmed A.; Berati H.; Nalan A.; Aylin S.; Effect of bevacizumab on corneal neovascularization in experimental rabbit model. Clin Exp Ophthalmol 2009,37(7),730-736","journal-title":"Clin Exp Ophthalmol"},{"key":"ref=156","first-page":"209","volume":"77","author":"Ozdemir O.","year":"2014","unstructured":"Ozdemir O.; Altintas O.; Altintas L.; Ozkan B.; Akdag C.; Y\u00fcksel N.; Comparison of the effects of subconjunctival and topical anti-VEGF therapy (bevacizumab) on experimental corneal neovascularization. Arq Bras Oftalmol 2014,77(4),209-213","journal-title":"Arq Bras Oftalmol"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"7376","DOI":"10.1167\/iovs.14-15257","volume":"55","author":"Kim Y.C.","year":"2014","unstructured":"Kim Y.C.; Grossniklaus H.E.; Edelhauser H.F.; Prausnitz M.R.; Intrastromal delivery of bevacizumab using microneedles to treat corneal neovascularization. Invest Ophthalmol Vis Sci 2014,55(11),7376-7386","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1590\/S0004-27492012000400012","volume":"75","author":"Vieira A.C.","year":"2012","unstructured":"Vieira A.C.; H\u00f6fling-Lima A.L.; Gomes J.\u00c1.; Freitas Dd, Farah ME, Belfort R Jr. Intrastromal injection of bevacizumab in patients with corneal neovascularization. Arq Bras Oftalmol 2012,75(4),277-279","journal-title":"Arq Bras Oftalmol"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1097\/00006982-200603000-00002","volume":"26","author":"Shahar J.","year":"2006","unstructured":"Shahar J.; Avery R.L.; Heilweil G.; Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 2006,26(3),262-269","journal-title":"Retina"},{"key":"ref=160","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.1167\/iovs.06-0433","volume":"47","author":"Costa R.A.","year":"2006","unstructured":"Costa R.A.; Jorge R.; Calucci D.; Cardillo J.A.; Melo L.A.; Scott I.U.; Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study. Invest Ophthalmol Vis Sci 2006,47(10),4569-4578","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1136\/bjo.2006.099598","volume":"90","author":"Fung A.E.","year":"2006","unstructured":"Fung A.E.; Rosenfeld P.J.; Reichel E.; The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006,90(11),1344-1349","journal-title":"Br J Ophthalmol"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1097\/ICO.0b013e3181ba0ae2","volume":"29","author":"Symes R.J.","year":"2010","unstructured":"Symes R.J.; Poole T.R.; Corneal graft surgery combined with subconjunctival bevacizumab (avastin). Cornea 2010,29(6),691-693","journal-title":"Cornea"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/j.1600-0420.1997.tb00623.x","volume":"75","author":"van Setten G.B.","year":"1997","unstructured":"van Setten G.B.; Vascular endothelial growth factor (VEGF) in normal human corneal epithelium: detection and physiological importance. Acta Ophthalmol Scand 1997,75(6),649-652","journal-title":"Acta Ophthalmol Scand"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"3870","DOI":"10.1167\/iovs.07-1418","volume":"49","author":"Yu C.Q.","year":"2008","unstructured":"Yu C.Q.; Zhang M.; Matis K.I.; Kim C.; Rosenblatt M.I.; Vascular endothelial growth factor mediates corneal nerve repair. Invest Ophthalmol Vis Sci 2008,49(9),3870-3878","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/ICO.0000000000001871","volume":"38","author":"Goldhardt R.","year":"2019","unstructured":"Goldhardt R.; Batawi H.I.M.; Rosenblatt M.; Lollett I.V.; Park J.J.; Galor A.; Effect of Anti-Vascular Endothelial Growth Factor Therapy on Corneal Nerves. Cornea 2019,38(5),559-564","journal-title":"Cornea"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2353\/ajpath.2007.061237","volume":"171","author":"Nishijima K.","year":"2007","unstructured":"Nishijima K.; Ng Y.S.; Zhong L.; Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 2007,171(1),53-67","journal-title":"Am J Pathol"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1007\/s00347-007-1569-y","volume":"104","author":"Kernt M.","year":"2007","unstructured":"Kernt M.; Welge-L\u00fcssen U.; Yu A.; Neubauer A.S.; Kampik A.;  Ophthalmologe [Bevacizumab is not toxic to human anterior- and posterior-segment cultured cells2007,104(11),965-971","journal-title":"Ophthalmologe"},{"key":"ref=168","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s10792-013-9807-6","volume":"34","author":"Lichtinger A.","year":"2014","unstructured":"Lichtinger A.; Yeung S.N.; Kim P.; Amiran M.D.; Elbaz U.; Slomovic A.R.; Corneal endothelial safety following subconjunctival and intrastromal injection of bevacizumab for corneal neovascularization. Int Ophthalmol 2014,34(3),597-601","journal-title":"Int Ophthalmol"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.survophthal.2010.08.006","volume":"56","author":"Tolentino M.","year":"2011","unstructured":"Tolentino M.; Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol 2011,56(2),95-113","journal-title":"Surv Ophthalmol"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1001\/jama.293.12.1509","volume":"293","author":"van Wijngaarden P.","year":"2005","unstructured":"van Wijngaarden P.; Coster D.J.; Williams K.A.; Inhibitors of ocular neovascularization: promises and potential problems. JAMA 2005,293(12),1509-1513","journal-title":"JAMA"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.2353\/ajpath.2006.050588","volume":"168","author":"Jo N.","year":"2006","unstructured":"Jo N.; Mailhos C.; Ju M.; Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol 2006,168(6),2036-2053","journal-title":"Am J Pathol"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.ajo.2010.04.024","volume":"150","author":"P\u00e9rez-Santonja J.J.","year":"2010","unstructured":"P\u00e9rez-Santonja J.J.; Campos-Mollo E.; Lled\u00f3-Riquelme M.; Javaloy J.; Ali\u00f3 J.L.; Inhibition of corneal neovascularization by topical bevacizumab (Anti-VEGF) and Sunitinib (Anti-VEGF and Anti-PDGF) in an animal model. Am J Ophthalmol 2010,150(4),519-528.e1","journal-title":"Am J Ophthalmol"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1080\/02713683.2017.1416146","volume":"43","author":"Lopez E.S.","year":"2018","unstructured":"Lopez E.S.; Ortiz G.A.; Potilinski C.; Croxatto J.O.; Gallo J.E.; Corneal Neovascularization: A Combined Approach of Bevacizumab and Suramin Showed Increased Antiangiogenic Effect Through Downregulation of BFGF and P2X2. Curr Eye Res 2018,43(4),466-473","journal-title":"Curr Eye Res"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1167\/iovs.04-0128","volume":"45","author":"Ma X.","year":"2004","unstructured":"Ma X.; Ottino P.; Bazan H.E.; Bazan N.G.; Platelet-activating factor (PAF) induces corneal neovascularization and upregulates VEGF expression in endothelial cells. Invest Ophthalmol Vis Sci 2004,45(9),2915-2921","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1097\/ICO.0b013e3182542613","volume":"32","author":"Papathanassiou M.","year":"2013","unstructured":"Papathanassiou M.; Theodoropoulou S.; Analitis A.; Tzonou A.; Theodossiadis P.G.; Vascular endothelial growth factor inhibitors for treatment of corneal neovascularization: a meta-analysis. Cornea 2013,32(4),435-444","journal-title":"Cornea"}],"container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/180363","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/180363\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/180363","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T16:38:29Z","timestamp":1611160709000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/180363\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,18]]},"references-count":175,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,9,18]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389450121666200319111710","relation":{},"ISSN":["1389-4501"],"issn-type":[{"value":"1389-4501","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,18]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-11-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-31","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}